236 related articles for article (PubMed ID: 3460691)
1. Effect of the interval between high dose 1-beta-D-arabinofuranosylcytosine injections on leukemic cell load, intestinal toxicity, and normal hematopoietic stem cells in a rat model for acute myelogenous leukemia.
Colly LP; Peters WG; Willemze R
Cancer Res; 1986 Aug; 46(8):3825-7. PubMed ID: 3460691
[TBL] [Abstract][Full Text] [Related]
2. Development of a cell kinetic approach to curative therapy of acute myelocytic leukemia in remission using the cell cycle-specific drug 1-beta-D-arabinofuranosylcytosine in a rat model.
Vaughan WP; Burke PJ
Cancer Res; 1983 May; 43(5):2005-9. PubMed ID: 6572561
[TBL] [Abstract][Full Text] [Related]
3. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J
Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678
[TBL] [Abstract][Full Text] [Related]
4. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
[TBL] [Abstract][Full Text] [Related]
5. Prediction of response to chemotherapy in acute leukemia by in vitro drug sensitivity testing on leukemic stem cells.
Gustavsson A; Olofsson T
Cancer Res; 1984 Oct; 44(10):4648-52. PubMed ID: 6590116
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
7. Enhanced tumor load reduction after chemotherapy induced recruitment and synchronization in a slowly growing rat leukemia model (BNML) for human acute myelocytic leukemia.
Colly LP; van Bekkum DW; Hagenbeek A
Leuk Res; 1984; 8(6):953-63. PubMed ID: 6595483
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Early AP; Preisler HD; Slocum H; Rustum YM
Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
[TBL] [Abstract][Full Text] [Related]
9. The effect of a prolonged in vitro exposure to 1-beta-D arabinofuranosylcytosine and deoxycytidine on the survival of normal (CFU-GM) and leukemic (L-CFU) human myeloid progenitor cells in suspension culture.
Grant S; Bhalla K; Arlin Z; Howe CW
Exp Hematol; 1990 Jan; 18(1):41-8. PubMed ID: 2298268
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response.
Burke PJ; Karp JE; Vaughan WP
J Natl Cancer Inst; 1981 Sep; 67(3):529-38. PubMed ID: 6944525
[TBL] [Abstract][Full Text] [Related]
11. In vivo studies on high-dose 1-beta-D-arabinofuranosylcytosine (HDara-C) and 1-beta-D-arabinofuranosyluracil (ara-U) with respect to pharmacokinetics, cell kinetics, and cytotoxicity in a rat myelocytic leukemia model (BNML).
Colly LP; Willemze R; Honders W; vd Hoorn F; Edelbroek PM
Semin Oncol; 1985 Jun; 12(2 Suppl 3):49-54. PubMed ID: 3859932
[TBL] [Abstract][Full Text] [Related]
12. Prevention of hematotoxic side effects of cytostatic drugs in mice by a synthetic hemoregulatory peptide.
Paukovits WR; Guigon M; Binder KA; Hergl A; Laerum OD; Schulte-Hermann R
Cancer Res; 1990 Jan; 50(2):328-32. PubMed ID: 2295072
[TBL] [Abstract][Full Text] [Related]
13. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
Liliemark JO; Plunkett W; Dixon DO
Cancer Res; 1985 Nov; 45(11 Pt 2):5952-7. PubMed ID: 4053067
[TBL] [Abstract][Full Text] [Related]
14. The enhanced cytotoxicity of combinations of 1-beta-D-arabinofuranosylcytosine and methotrexate.
Edelstein M; Vietti T; Valeriote F
Cancer Res; 1975 Jun; 35(6):1555-8. PubMed ID: 1131822
[TBL] [Abstract][Full Text] [Related]
15. Effect of the interval between exposures to cytarabine on its cytotoxic action on HL-60 myeloid leukemic cells.
Leclerc JM; Momparler RL
Cancer Treat Rep; 1984 Sep; 68(9):1143-8. PubMed ID: 6592037
[TBL] [Abstract][Full Text] [Related]
16. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
Blumenreich MS; Chou TC; Andreeff M; Vale K; Clarkson BD; Young CW
Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
[TBL] [Abstract][Full Text] [Related]
17. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
Avramis VI; Biener R; Krailo M; Finklestein J; Ettinger L; Willoughby M; Siegel SE; Holcenberg JS
Cancer Res; 1987 Dec; 47(24 Pt 1):6786-92. PubMed ID: 3479250
[TBL] [Abstract][Full Text] [Related]
18. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
Bhalla K; Nayak R; Grant S
Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
[TBL] [Abstract][Full Text] [Related]
19. Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia.
Schwartz SA; Morgenstern B; Capizzi RL
Cancer Res; 1982 Jun; 42(6):2191-7. PubMed ID: 7074600
[TBL] [Abstract][Full Text] [Related]
20. Interferon protects normal human granulocyte/macrophage colony-forming cells from Ara-C cytotoxicity.
Richman CM; Slapak CA; Toh B
J Biol Response Mod; 1990 Dec; 9(6):570-5. PubMed ID: 1705960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
